Log in to save to my catalogue

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8531987

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

About this item

Full title

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2021-12, Vol.385 (23), p.2140-2149

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In an Israeli Ministry of Health database, 136 definite or probable cases of myocarditis were detected among 5 million vaccinated persons. The rate ratio after two doses as compared with unvaccinated persons was 2.35, with the highest risk among male recipients between the ages of 16 and 19 years.

Alternative Titles

Full title

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8531987

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8531987

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2109730

How to access this item